Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage

Continuous erythropoietin receptor activator (CERA) seems to maintain a stable hemoglobin (Hb) level because its half-life is longer than darbepoetin α (DA). Twenty chronic kidney disease (CKD) patients at the pre-dialysis stage who had been administered DA for over 24 weeks were randomly assigned t...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Tetsuya, Okada, Kazuyoshi, Abe, Masanori, Tei, Ritsukou, Oikawa, Osamu, Maruyama, Noriaki, Maruyama, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691171/
https://www.ncbi.nlm.nih.gov/pubmed/26694377
http://dx.doi.org/10.3390/ijms161226229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691171/
https://www.ncbi.nlm.nih.gov/pubmed/26694377
http://dx.doi.org/10.3390/ijms161226229

Ejemplares similares